Citadel Advisors
QNCX icon

Citadel Advisors’s Quince Therapeutics QNCX Stock Holding History

Citadel Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.6K Buy
670
+515
+332% +$103K ﹤0.01% 12722
2025
Q4 		$104K Buy
155
+84
+118% +$42.3K ﹤0.01% 11610
2025
Q3 		$23K Buy
+71
New +$23.6K ﹤0.01% 12463
2025
Q2 		– Sell
-42
Closed -$11.2K – 14598
2025
Q1 		$11.2K Sell
42
-198
-83% -$60.5K ﹤0.01% 13501
2024
Q4 		$89.6K Buy
240
+207
+627% +$62.2K ﹤0.01% 11642
2024
Q3 		$5.12K Buy
33
+18
+120% +$2.58K ﹤0.01% 13518
2024
Q2 		$2.25K Buy
15
+7
+88% +$1.26K ﹤0.01% 13715
2024
Q1 		$1.7K Buy
+8
New +$1.99K ﹤0.01% 14096
2023
Q3 		– Sell
-64
Closed -$19.1K – 14951
2023
Q2 		$19.1K Sell
64
-13
-17% -$4.05K ﹤0.01% 12762
2023
Q1 		$24K Sell
77
-604
-89% -$118K ﹤0.01% 12920
2022
Q4 		$86.8K Sell
681
-22
-3% -$3.68K ﹤0.01% 11411
2022
Q3 		$187K Buy
703
+77
+12% +$29.3K ﹤0.01% 10469
2022
Q2 		$278K Sell
626
-184
-23% -$130K ﹤0.01% 9965
2022
Q1 		$1M Sell
810
-581
-42% -$791K ﹤0.01% 7685
2021
Q4 		$3.51M Buy
1,391
+772
+125% +$4.71M ﹤0.01% 5025
2021
Q3 		$11.3M Buy
619
+309
+100% +$4.91M ﹤0.01% 2852
2021
Q2 		$3.28M Buy
310
+82
+36% +$688K ﹤0.01% 5380
2021
Q1 		$1.64M Buy
228
+181
+385% +$1.3M ﹤0.01% 6879
2020
Q4 		$261K Buy
+47
New +$416K ﹤0.01% 9313

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's QNCX Position: Q1 2026 in Review

Citadel Advisors sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 780 shares — an estimated $157K sold.

Citadel Advisors first reported a position in QNCX in Q3 2019 and held it in 18 quarters. The position peaked at $16M in Q2 2020. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Citadel Advisors reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 780 Quince Therapeutics shares in Q1 2026, an estimated $157K.
  • Citadel Advisors first reported a position in Quince Therapeutics in Q3 2019 and held it in 18 quarters.
  • Citadel Advisors's Quince Therapeutics position peaked at $16M in Q2 2020.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.